Navigation Links
Smithsonian Explores Beginnings of Biotechnology
Date:10/24/2013

WASHINGTON, Oct. 24, 2013 /PRNewswire/ -- The Smithsonian's National Museum of American History chronicles the story of biotechnology and its impact on society in a new showcase display, "The Birth of Biotech," which opens Oct. 25. The display, located in a first floor History Highlights Case, will explore the science and industry behind the first major product of the biotech boom—recombinant human insulin. Made by genetically modified bacteria, recombinant human insulin provided a steady source of a vital diabetes drug, which replaced a less certain supply of animal-derived insulin. The display features lab and factory equipment from Genentech initially used to produce recombinant human insulin as well as historic objects used for managing and treating diabetes from the 1930s to the 1980s.

(Logo:  http://photos.prnewswire.com/prnh/20131024/NY03122LOGO )

"The story of biotechnology inspires the type of critical and inventive thinking that has allowed Americans to excel in emerging technologies throughout the nation's history," said Museum Director John Gray. "The museum helps visitors to understand these past advances as a foundation for future progress."

The museum began collecting biotech history in the 1980s, a collection that now includes more than 130 objects from Genentech.

"At Genentech, we are pleased to have been a spark that helped ignite the biotechnology industry nearly 40 years ago and are honored that the Smithsonian has so thoughtfully curated these artifacts to share with the American people," said Ian Clark, CEO of Genentech. "While our industry is young in comparison to many, biotechnology's innovations are significant. The industry collectively has helped millions of patients through more than 200 new medicines to treat a wide range of diseases including cancer, HIV/AIDS and autoimmune disorders."

The case opening will coincide with a special panel discussion and webcast presented by Genentech on Oct. 24 at 7 p.m. EDT. "The DNA Effect" panel will examine the impact of biotechnology on medicine and science, and what can be expected from the industry in the years to come. Panelists include: Arthur D. Levinson, Ph.D., chairman of the board, Genentech and chairman of the board, Apple; Dr. Kimberley L. Blackwell, professor of medicine, Duke Cancer Institute; George M. Church, Ph.D., Robert Winthrop Professor of Genetics, Harvard Medical School; and Dr. Daniel Kraft, executive director, FutureMed. The panel discussion will be webcast live at: www.gene.com/biotech.

In the early 1970s, a research team led by Herbert Boyer of the University of California at San Francisco and Stanley Cohen of Stanford University successfully transferred a gene from one species into another. Known as recombinant DNA, this discovery gave scientists across the world a tool to study life and disease at the molecular level, and has gone on to be a foundation of modern medicine. Boyer then teamed with venture capitalist Robert Swanson to form Genentech.

"The recombinant DNA technique allowed biotechnologists to transform the bacteria E. coli into tiny factories to produce insulin and other therapeutic proteins," said Ann Seeger, deputy chair of the museum's Division of Medicine and Science. "Visitors will see how the emergence of biotechnology highlights an important aspect of the American experience illustrating a relationship between science, industry and enterprise that has often fueled our country's economic growth."

Through its collections, research and public outreach, the National Museum of American History explores the infinite richness and complexity of American history. It helps people understand the past in order to make sense of the present and shape a more humane future. The museum is currently renovating its west exhibition wing, developing galleries on business, democracy and culture. For more information, visit http://americanhistory.si.edu. The museum is located at 14th Street and Constitution Avenue N.W., and is open daily from 10 a.m. to 5:30 p.m. (closed Dec. 25). Admission is free. For Smithsonian information, the public may call (202) 633-1000.

Contacts:
Valeska Hilbig
Smithsonian
(202) 633-3129; hilbigv@si.edu

Lisa Slater
Genentech
(650) 350-2154; slater.lisa@gene.com


'/>"/>
SOURCE Smithsonian's National Museum of American History
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Leadership as a Hero’s Journey Explores Four Virtues That Transform Uncertainty and Anxiety into Results, a New Book by Eric Kaufmann
2. DuPont Realigns Leadership Team to Accelerate Integrated Science Execution, Explores Strategic Alternatives for Performance Chemicals
3. New Online Course Explores Mouse as Model for Prostate Cancer
4. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
5. How to Do Spring Cleaning the Healthy Way: DistinctBright Explores the Overlooked Dangers of Household Cleaning Products and offers Natural Cleaning Solutions
6. Notre Dame study explores the potential benefits and threats of nanotechnology research
7. Clinverse’s ClinPay Automated Solution Streamlines Investigator Payment Process for a Biotechnology Innovator
8. Plant Health Scientists Reiterate Support of Biotechnology on World Food Day
9. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
10. UMBC’s Biotechnology Graduate Programs Virtual Info Session, October 17, 2013
11. Evonik and Genedata Broaden Their Collaboration with the Genedata Selector Biotechnology Data Management Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):